Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development

MaxCyte announces the introduction of its ITF Inline Transfection System, a validated platform for preparative transfection, based on flow electroporation technology. This system can enable transfection of any kind of cell or cell line with any molecule (plasmids, proteins, protein complexes, drugs, mRNA, siRNA), at scales ranging from micro-liters to liter volumes.

MaxCyte's ITF Inline Transfection System enables transient transfection of cell lines as well as primary cells, and is now available for drug discovery and screening applications. The sterile, closed system provides unparalleled consistency, scalability, and loading efficiency while avoiding the inherent drawbacks of alternative methods.

Many cell based assays and research projects are based on recombinant cell lines. Optimizing such cell lines so they express a desired set of properties and are compatible with a particular screening platform takes considerable time and expense. Because of its ease and speed, transient transfection is used to replace cloning and recombinant work in a wide range of applications (e.g. ion channel based drug or GPCR screening).

MaxCyte ITF Inline Transfection system replaces current preparative transfection technologies which depend on expensive and complicated virus constructs, lipid based transfection agents, or small scale electroporation devices.

According to company, the efficiency and viability of cells processed by the MaxCyte ITF Inline Transfection System make it possible to focus on biologically relevant cell lines, and even primary cells. Inline transfection is also fully scalable. It can be used to transfect 10^5 - 10^7 cells in seconds and up to 10^10 cells in less than 30 minutes. Viability is routinely greater than 90%, with more than 90% cell loading and transfection efficiency for many cell lines. Protocols are available for a wide range of cell lines and primary cells.